Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1980;97(3):301-6.
doi: 10.1007/BF00405782.

Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma

R Becher, S Seeber, C G Schmidt

Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma

R Becher et al. J Cancer Res Clin Oncol. 1980.

Abstract
in English, German

Twenty-five patients with measurable lesions of advanced malignant melanoma received a combined chemotherapy containing cis-dichlordiammineplatinum (II) (cisplatin) 30 mg daily at days 1, 3, 5, 7, 9, and ifosfamide 45 mg/kg at days 2, 4, 6, 8, and 10. Most of the patients had been previously treated with DTIC or DTIC-containing combinations. An objective response was observed in 10 patients including three complete and seven partial remissions. Medium survival was 3 months for nonresponders and 6 months for responders. Nausea and vomiting during chemotherapy could be reduced effectively be the use of levomepromacine (Neurocil). Hematologic toxicity was considerable in extensively pretreated patients and made it necessary to postpone subsequent courses in two cases.

Fünfundzwanzig Patienten mit metastasierendem malignem Melanom und gut dokumentierbaren Tumorparametern wurden mit einer kombinierten zytostatischen Chemotherapie, bestehend aus Cisplatin und Ifosfamid, behandelt. Cisplatin wurde an den Tagen 1, 3, 5, 7 und 9 in der Tagesdosis von 30 mg und Ifosfamid in einer Dosis von 45 mg/kg an den Tagen 2, 4, 6, 8 und 10 verabreicht. Die meisten Patienten waren zuvor mit DTIC oder DTIC-haltigen zytostatischen Kombinationen behandelt worden. In drei Fällen wurde eine komplette Remission und in sieben Fällen eine Teilremission mit über 50% Tumorreduktion erreicht. Die mittlere Überlebenszeit betrug für therapieresistente Fälle 3 Monate und für Ansprecher 6 Monate. Erbrechen und Übelkeit während der Behandlung konnte durch die Verabreichung von Levomepromazin (Neurocil) reduziert werden. Die hämatologische Toxizität war bei intensiv vorbehandelten Patienten erheblich und machte eine Verlängerung des therapiefreien Intervalls in zwei Fällen erforderlich.

PubMed Disclaimer

References

    1. Ahmann DL, Edmonson JH, Frytak S, Kvols LK, Bisel HF, Rubin J (1978) Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum (II) and DTIC in patients with disseminated malignant melanoma. Cancer Treatment Rep 62:151–153 - PubMed
    1. Al-Sarraf M (1979) Clinical trial of cis-platinum (NSC-119875): Hydratation with and without mannitol in patients with previously treated advanced malignant melanoma. A Southwest Oncology Group Study. Proc Am Assoc Cancer Res 20:185, Abstr 746
    1. Chary KK, Higby DJ, Henderson ES, Swinerton KD (1977) Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis. Cancer Treatment Rep 61:367–370 - PubMed
    1. DeVita VT Jr, Fisher RI (1976) Natural history of malignant melanoma as related to therapy. Cancer Treatment Rep 60:153–157 - PubMed
    1. Einhorn LH, Burgess MA, Vallejos C, Bodey GP, Gutterman J, Mavligit G, Hersh EM, Luce JK, Frei E III, Freireich EJ, Gottlieb JA (1974) Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res 34:1995–2004 - PubMed

LinkOut - more resources